Imexon
- Generic Name
- Imexon
- Drug Type
- Small Molecule
- Chemical Formula
- C4H5N3O
- CAS Number
- 59643-91-3
- Unique Ingredient Identifier
- 8F63U28T2V
Overview
Imexon is currently being studied for the treatment of pancreatic, lung, breast, prostate, melanoma, and multiple myeloma cancers. It belongs to the family of drugs called cyanoaziridine derivatives. Also called Amplimexon. Imexon is a cyanoaziridine derivative. Imexon is a thiol-binding small molecule which induces mitochondrial oxidation, a loss of membrane potential and cytochrome C, leading to apoptosis.
Background
Imexon is currently being studied for the treatment of pancreatic, lung, breast, prostate, melanoma, and multiple myeloma cancers. It belongs to the family of drugs called cyanoaziridine derivatives. Also called Amplimexon. Imexon is a cyanoaziridine derivative. Imexon is a thiol-binding small molecule which induces mitochondrial oxidation, a loss of membrane potential and cytochrome C, leading to apoptosis.
Indication
Investigated for use/treatment in melanoma, multiple myeloma, ovarian cancer, pancreatic cancer, and solid tumors.
Associated Conditions
No associated conditions information available.
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.